American buyers took $15.06 billion of medicines from India in 2025. The same American institutions that hold the largest positions in American drug companies hold, indirectly, a position in that supply. The two numbers are rarely read together.

Start with the trade. Among all countries selling medicines into the United States in 2025, Ireland sold $42.57 billion, Germany $26.11 billion, Switzerland $19.44 billion, India $15.06 billion, Belgium $11.97 billion and France $11.53 billion. India is fourth. The year before it sold $12.47 billion. That is growth of about 21 percent in twelve months. (See also: India-United States trade)

The share is the more useful measure, because it survives price inflation and dollar movement. The United States bought $211.58 billion of medicines from all sources in 2025, so India supplied about 7.1 percent of the whole. In 2020 that share was 6.3 percent. The gain is eight tenths of a percentage point across five years, and India took it without displacing any of the three suppliers above it. Ireland, Germany and Switzerland between them sold $88.12 billion, or 41.6 percent of everything the United States imported. Add India and the top four account for 48.8 percent. The rest of the world supplies the other half between them. Supplier share in this market moves slowly for a structural reason: replacing an approved source of an active ingredient or a finished generic requires requalifying the substitute, through regulatory filing and plant inspection. Positions built that way are correspondingly slow to lose. Ireland's position at the top of the list is not the same kind of fact. Much of what Ireland ships is American companies manufacturing under their own corporate structures, so a large share of the flow is intra-firm and answers to tax and corporate siting as well as to procurement. (See also: farmed shrimps and prawns)

The longer series is steadier still. Counting medicines together with the organic chemistry that feeds them, India sold $10.99 billion into the United States in 2020 and $19.13 billion in 2025. The figure roughly doubled in five years. That is compound growth of about 11.7 percent a year, sustained through a pandemic and through two years in which freight rates behaved abnormally. (See also: India-United States trade)

Against that supply picture, consider what the largest American institutions actually hold. On 31 March 2026, State Street reported $32.75 billion of Eli Lilly, a single position worth 1.131 percent of its entire reported portfolio. Fidelity reported $16.72 billion of the same company. In Pfizer on that date, State Street reported $8.47 billion, Point72 reported $122.6 million and D.E. Shaw reported $107.8 million.

None of those positions is a view on India, and none should be read as one. Eli Lilly carries a market value near $951 billion on revenue of about $79.67 billion. Johnson and Johnson turns over roughly $97.93 billion. American fundamentals account for the holdings without reference to any supplier.

The input chain beneath them is a separate question, and it is not covered by the same analysis. A percentage point of a book held in one drug company is also, unavoidably, a position on that company's suppliers. Active ingredients, intermediates and finished generics are manufactured somewhere, and a growing share of that manufacturing is done in India. Therapeutic risk and patent expiry are standard inputs to a pharmaceutical valuation and are priced accordingly. Concentration of origin in the input chain is not standard. A supplier that has moved from 6.3 to 7.1 percent of American medicine imports in five years, in a market where switching requires requalification, is a position that will be harder to unwind the longer it holds.

A second flow runs the other way and is larger than its public profile suggests. Indian companies have committed $50.40 billion into the United States since 2011, across 18,661 separate investment transactions involving 8,608 distinct Indian firms. Those are regulatory filings current to April 2026, so the figure records capital actually committed, not capital announced.

Since April 2025 alone, Indian firms committed $4.75 billion into American financial, insurance and business services across 1,443 transactions, and $1.33 billion into manufacturing across 489. The manufacturing total is the smaller of the two and the slower to reverse. Services capacity can be stood up and wound down inside a contract cycle; a plant is sited, permitted and staffed for a decade.

Through the first five months of 2026, the combined medicines and chemistry figure stands at $5.86 billion. Customs series fill in as filings are processed, so the most recent months of any extract read light and revise upward for some time afterwards. Scaling five incomplete months to a full year would carry that undercount into the annual number and hide it. The measured position is $5.86 billion through May.

A supply relationship growing at 21 percent a year is governed by supply agreements and qualification approvals that are not disclosed when they are made. Their effect becomes observable later, and only indirectly, through the cost of goods sold of the companies on either side. What is available now is narrower but public: customs records at the tariff line, and the ownership and investment filings cited here.

James Sterling is Chief Executive Officer of US Operations at Zovora AI Technologies, Inc., based in New York. Trade figures are United States customs records at the ten-digit tariff line. Investment figures are Reserve Bank of India outbound filings current to April 2026. Holdings are as reported on 31 March 2026.